Literature DB >> 22547345

Probing into the biological processes influenced by ESC factor and oncoprotein HMGA2 using iPSCs.

Amir Morshedi1, Zhonglu Ren, Jinming Li, Peter Dröge.   

Abstract

Induced pluripotent stem cells (iPSCs) are rapidly evolving into an important research tool due to their close resemblance with pluripotent embryonic stem cells (ESCs). Of particular interest at this point are iPSC applications in disease modeling and drug discovery/testing. The high mobility group AT-hook 2 (HMGA2) protein is a nonhistone chromatin factor normally expressed in ESCs and during early developmental stages. Aberrant HMGA2 expression is associated, for example, with abnormal body stature, diabetes mellitus, heart development and uterine leiomyomas. Furthermore, the protein is re-expressed in many primary tumor cells and plays an important role in metastasis. Here we used iPSC formation in conjunction with exogenous human HMGA2 expression to gain insight into biological functions of HMGA2. Gene expression profiling and gene ontology analyses showed that anatomical development and cell adhesion/differentiation processes are strongly affected by HMGA2. This could help to uncover, at the molecular level, some of the known phenotypic consequences of aberrant HMGA2 expression. Furthermore, our data showed that expression of key diabetes susceptibility genes is influenced by HMGA2, which revealed an interesting link to the recently indentified Lin28/let-7 pathway regulating mammalian glucose metabolism. Contrary to a previous report, our results indicate that HMGA2 is not involved in the regulation of telomerase gene expression. Finally, our data support a model in which tight regulation of intracellular HMGA2 levels is important both to maintain a pluripotent ESC state and to induce differentiation into certain cell lineages during later developmental stages.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22547345     DOI: 10.1007/s12015-012-9373-8

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  45 in total

1.  Ink4a/Arf regulation by let-7b and Hmga2: a genetic pathway governing stem cell aging.

Authors:  Alexandros Tzatsos; Nabeel Bardeesy
Journal:  Cell Stem Cell       Date:  2008-11-06       Impact factor: 24.633

2.  The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif.

Authors:  J R Huth; C A Bewley; M S Nissen; J N Evans; R Reeves; A M Gronenborn; G M Clore
Journal:  Nat Struct Biol       Date:  1997-08

3.  The evolving biology of cell reprogramming.

Authors:  Ian Wilmut; Gareth Sullivan; Ian Chambers
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

4.  A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells.

Authors:  Leslie Caron; Frédéric Bost; Matthieu Prot; Paul Hofman; Bernard Binétruy
Journal:  Oncogene       Date:  2005-09-15       Impact factor: 9.867

5.  Evaluation of SNPs in the chicken HMGA2 gene as markers for body weight gain.

Authors:  C Song; X Gu; C Feng; Y Wang; Y Gao; X Hu; N Li
Journal:  Anim Genet       Date:  2010-12-01       Impact factor: 3.169

6.  A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation.

Authors:  Masashi Narita; Masako Narita; Valery Krizhanovsky; Sabrina Nuñez; Agustin Chicas; Stephen A Hearn; Michael P Myers; Scott W Lowe
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

7.  SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.

Authors:  Xuefei Cao; Carlos Clavijo; Xu Li; H Helen Lin; Yuan Chen; Hsiu-Ming Shih; David K Ann
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

8.  HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.

Authors:  Gennaro Chiappetta; Angelo Ferraro; Emilia Vuttariello; Mario Monaco; Francesca Galdiero; Veronica De Simone; Daniela Califano; Pierlorenzo Pallante; Gerardo Botti; Luciano Pezzullo; Giovanna Maria Pierantoni; Massimo Santoro; Alfredo Fusco
Journal:  Eur J Cancer       Date:  2008-03-28       Impact factor: 9.162

9.  Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas.

Authors:  P Arlotta; A K Tai; G Manfioletti; C Clifford; G Jay; S J Ono
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

10.  Common variants in the GDF5-UQCC region are associated with variation in human height.

Authors:  Serena Sanna; Anne U Jackson; Ramaiah Nagaraja; Cristen J Willer; Wei-Min Chen; Lori L Bonnycastle; Haiqing Shen; Nicholas Timpson; Guillaume Lettre; Gianluca Usala; Peter S Chines; Heather M Stringham; Laura J Scott; Mariano Dei; Sandra Lai; Giuseppe Albai; Laura Crisponi; Silvia Naitza; Kimberly F Doheny; Elizabeth W Pugh; Yoav Ben-Shlomo; Shah Ebrahim; Debbie A Lawlor; Richard N Bergman; Richard M Watanabe; Manuela Uda; Jaakko Tuomilehto; Josef Coresh; Joel N Hirschhorn; Alan R Shuldiner; David Schlessinger; Francis S Collins; George Davey Smith; Eric Boerwinkle; Antonio Cao; Michael Boehnke; Gonçalo R Abecasis; Karen L Mohlke
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

View more
  10 in total

1.  End of inevitability: programming and reprogramming.

Authors:  Kursad Turksen
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

2.  The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma.

Authors:  Harpreet Kaur; Sabeen Zulfiqar Ali; Lauren Huey; Marianne Hütt-Cabezas; Isabella Taylor; Xing-Gang Mao; Melanie Weingart; Qian Chu; Fausto J Rodriguez; Charles G Eberhart; Eric H Raabe
Journal:  Cancer Lett       Date:  2016-04-18       Impact factor: 8.679

3.  HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation.

Authors:  Junying Sun; Baocun Sun; Dongwang Zhu; Xiulan Zhao; Yanhui Zhang; Xueyi Dong; Na Che; Jing Li; Fang Liu; Nan Zhao; Danfang Zhang; Tieju Liu; Xian Lin
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

4.  The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity.

Authors:  Harpreet Kaur; Marianne Hütt-Cabezas; Melanie F Weingart; Jingying Xu; Yasumichi Kuwahara; Anat Erdreich-Epstein; Bernard E Weissman; Charles G Eberhart; Eric H Raabe
Journal:  J Neuropathol Exp Neurol       Date:  2015-02       Impact factor: 3.685

5.  Downregulation of HMGA2 by Small Interfering RNA Affects the Survival, Migration, and Apoptosis of Prostate Cancer Cell Line.

Authors:  Shima Khajouee; Elham Baghbani; Ali Mohammadi; Behzad Mansoori; Dariush Shanehbandi; Khalil Hajiasgharzadeh; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2021-04-03

Review 6.  HMGA2 and high-grade serous ovarian carcinoma.

Authors:  Jingjing Wu; Jian-Jun Wei
Journal:  J Mol Med (Berl)       Date:  2013-05-19       Impact factor: 4.599

Review 7.  Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression.

Authors:  Linda Resar; Lionel Chia; Lingling Xian
Journal:  Cancer Res       Date:  2018-04-04       Impact factor: 12.701

8.  Enamel matrix derivative promote primary human pulp cell differentiation and mineralization.

Authors:  Elisabeth Aurstad Riksen; Maria A Landin; Sjur Reppe; Yukio Nakamura; Ståle Petter Lyngstadaas; Janne E Reseland
Journal:  Int J Mol Sci       Date:  2014-05-05       Impact factor: 5.923

9.  Utf1 contributes to intergenerational epigenetic inheritance of pluripotency.

Authors:  Qiuye Bao; Amir Morshedi; Fulu Wang; Sharma Bhargy; Konstantin Pervushin; Wei-Ping Yu; Peter Dröge
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

10.  HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients.

Authors:  Lourdes Hontecillas-Prieto; Daniel J García-Domínguez; Rosa García-Mejías; Gema L Ramírez-Villar; Carmen Sáez; Enrique de Álava
Journal:  Oncotarget       Date:  2017-12-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.